The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute
myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor
cells and the most common and severe malignant leukemia in adults and is responsible for the
highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant
lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal
blood cell lineages.
The primary objectives of this study are investigating the safety, tolerability, and the MTD
of LBS-007. The secondary objectives are to assess the efficacy and to determine the
pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the
changes in surrogate biomarkers in response to treatment.